Professor and interim head of pathobiology Mark Kuhlenschmidt is part of a team that will develop a new system to study a parasite, Cryptosporidium, which causes a diarrheal disease in humans.
The University of Illinois is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation. Daniel L. Rock, a professor of pathobiology, and Mark S. Kuhlenschmidt, a professor and the interim head of pathobiology, will pursue innovative global health and development research projects.
A new study found that the targeted culling of deer prevents the rampant spread of chronic wasting disease to healthy deer.
Chronic wasting disease, the deer-equivalent of mad cow disease, has crept across the U.S. landscape from west to east. It appeared first in captive mule deer in Colorado in the late 1960s. By 1981, it had escaped to the wild. It reached the Midwest by 2002. Little is known about its potential to infect humans.
Peter D. Constable, the head of the department of veterinary clinical sciences at Purdue University, will return to the U. of I. as the dean of the College of Veterinary Medicine, pending approval by the U. of I. Board of Trustees.
Peter D. Constable, a Purdue University professor of veterinary clinical sciences and the head of that department, will become the dean of the U. of I. College of Veterinary Medicine in January 2014, pending approval of the U. of I. Board of Trustees.
A topical general anesthetic for amphibians developed by veterinary researchers at Illinois could be a low-cost, easy-to-administer tool for scientists conducting research in the field. Cane toads were used in the study.
Veterinary researchers at the University of Illinois have developed a general anesthetic for amphibians that is administered through their skin. The anesthetic jelly could be a low-cost, easy-to-administer form of anesthesia for veterinary work conducted in the field.
Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.